SCHEMBL31269149

SCHEMBL31269149

Cc1ccccc1Cn1c(-c2ccc(OCCC(=O)O)cc2Cl)nc2c(OC3(C)CC3)ncnc21

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 2/20 0.36
▸ CNR2 P34972 2/20 0.36
▸ PIK3CD O00329 2/20 0.35
▸ ALOX5AP P20292 3/20 0.33
▸ PLA2G2A P14555 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ THRA P10827 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ RXRA P19793 3/20 0.32
▸ RXRB P28702 3/20 0.32
▸ RXRG P48443 2/20 0.32
▸ PDK2 Q15119 1/20 0.32
▸ MCL1 Q07820 2/20 0.32
▸ FFAR4 Q5NUL3 1/20 0.32
▸ PPARG P37231 1/20 0.31
▸ PPARD Q03181 1/20 0.31
▸ PPARA Q07869 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31268849 0.95 PIK3CD (0.37) CNR1CNR2PIK3CDALOX5APPLA2G2A
SCHEMBL31321937 0.92 PLA2G2A (0.40) PIK3CDPLA2G2ARXRARXRBRXRG
SCHEMBL31268962 0.92 PIK3CD (0.36) CNR1CNR2PIK3CDPLA2G2ARXRA
SCHEMBL31269288 0.87 PLA2G2A (0.36) PIK3CDALOX5APPLA2G2ATHRATHRB
SCHEMBL31269035 0.87 CNR1 (0.36) CNR1PIK3CDPLA2G2AFFAR4PPARG
SCHEMBL31269340 0.87 S1PR1 (0.36) PIK3CDPLA2G2AFFAR4
SCHEMBL31269325 0.85 S1PR1 (0.39) PIK3CDALOX5APPLA2G2ATHRATHRB
SCHEMBL30983954 0.84 PLA2G2A (0.39) CNR1CNR2PIK3CDALOX5APPLA2G2A
SCHEMBL30983583 0.84 PIK3CD (0.34) CNR1CNR2PIK3CDPLA2G2A
SCHEMBL30983523 0.84 PLA2G2A (0.38) CNR1PIK3CDPLA2G2AFFAR4PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
Send feedback